```html

Koch Disease (Tuberculosis) – Comprehensive Medical Guide

Overview

Tuberculosis (TB), also known as Koch disease after the German physician Robert Koch who discovered the causative bacterium in 1882, is an infectious disease caused by Mycobacterium tuberculosis. It most commonly involves the lungs (pulmonary TB) but can affect virtually any organ (extrapulmonary TB).

Each year, roughly 10 million people develop active TB worldwide, and about 1.5 million die from the disease, making it the leading cause of death from a single infectious agent—ahead of HIV/AIDS (WHO, 2023). The burden is highest in low‑ and middle‑income countries, especially in South‑East Asia, Africa, and the Western Pacific. In the United States, the CDC reported **8,300** cases in 2022, a rate of 2.5 per 100,000 people (CDC, 2023).

TB can affect anyone, but risk is higher in people with weakened immune systems, close contact with an infected person, or living in crowded or poorly ventilated environments.

Symptoms

Symptoms differ between latent infection (no symptoms) and active disease. The following list pertains to **active TB**:

• Persistent cough – lasting > 3 weeks; may produce sputum or blood.
• Chest pain – especially when breathing or coughing.
• Fever – low‑grade (usually 37.5–38.5 °C) and often worse in the evenings.
• Night sweats – soaking the bedclothes.
• Unexplained weight loss – “the consumption” historically described this.
• Fatigue and weakness – chronic tiredness despite rest.
• Loss of appetite.
• Hemoptysis – coughing up blood, a red‑flag sign.
• Shortness of breath – if extensive lung involvement.

Extrapulmonary TB may present with organ‑specific symptoms:

• Lymph node TB – painless, enlarged nodes, usually in the neck.
• Spinal (Pott) disease – back pain, stiffness, neurological deficits.
• TB meningitis – severe headache, neck stiffness, altered mental status.
• Genitourinary TB – pain during urination, blood in urine.
• Bone‑joint TB – swelling and pain in joints.

Causes and Risk Factors

Cause

TB is transmitted through airborne droplets when a person with active pulmonary or laryngeal TB coughs, sneezes, speaks, or sings. The bacteria can remain viable in the air for several hours, especially in poorly ventilated spaces. Inhalation of as few as 10–15 bacilli can initiate infection.

Risk Factors

• Immunosuppression – HIV infection (most important), diabetes, chronic kidney disease, malignancy, or use of corticosteroids/biologics.
• Close contact with someone who has contagious TB.
• Living conditions – overcrowded housing, prisons, homeless shelters, refugee camps.
• Substance use – smoking, alcohol misuse, illicit drug injection.
• Malnutrition – weakens immune defenses.
• Age – children < 5 years and the elderly have higher risk of progression from infection to disease.
• Geographic exposure – travel or residence in high‑burden countries.

Diagnosis

Accurate diagnosis combines clinical assessment, imaging, and microbiologic testing.

1. Medical History & Physical Examination

Physicians inquire about cough duration, weight loss, travel, exposure to TB, and risk‑modifier conditions (e.g., HIV). A focused exam looks for lung findings, lymphadenopathy, or signs of extrapulmonary disease.

2. Tuberculin Skin Test (TST) or Interferon‑γ Release Assays (IGRA)

Both detect immune sensitization to TB antigens.

• TST (Mantoux) involves intradermal injection of purified protein derivative; induration ≥10 mm (or ≥5 mm in high‑risk groups) after 48–72 h is considered positive.
• IGRA (e.g., QuantiFERON‑TB Gold) measures interferon‑γ release in blood; it is not affected by prior BCG vaccination and requires only one visit.

These tests cannot differentiate latent infection from active disease; they are mainly used to screen high‑risk individuals.

3. Chest Radiography

A postero‑anterior (PA) chest X‑ray can reveal:

• Upper‑lobe infiltrates or cavitary lesions.
• Hilar lymphadenopathy.
• Diffuse nodular patterns in miliary TB.

Radiographic findings must be interpreted with clinical context, as they can be normal in early disease.

4. Microbiologic Confirmation

The gold standard is identification of M. tuberculosis in respiratory specimens.

• Sputum smear microscopy – Ziehl‑Neelsen or fluorescent staining; rapid but less sensitive (≈50 % in HIV‑positive).
• Sputum culture – Solid (Löwenstein‑Jensen) or liquid (MGIT) media; most sensitive, allows drug‑susceptibility testing; results in 2–8 weeks.
• Nucleic acid amplification tests (NAAT) – e.g., Xpert MTB/RIF; detects DNA within hours and simultaneously identifies rifampin resistance (CDC, 2021).

5. Extrapulmonary Samples

Depending on the site, cultures or PCR from cerebrospinal fluid, pleural fluid, lymph node biopsy, or bone tissue may be needed.

6. Drug‑Susceptibility Testing (DST)

Essential for guiding therapy, especially in areas with multidrug‑resistant TB (MDR‑TB) or extensively drug‑resistant TB (XDR‑TB).

Treatment Options

Standard regimens differ for drug‑susceptible TB, MDR‑TB, and latent infection.

1. Drug‑Susceptible Pulmonary TB

The World Health Organization (WHO) recommends a **6‑month** regimen:

• **Intensive phase (2 months)** – Isoniazid (INH) + Rifampin (RIF) + Pyrazinamide (PZA) + Ethambutol (EMB).
• **Continuation phase (4 months)** – INH + RIF.

Directly observed therapy (DOT) is advised to ensure adherence.

2. Latent TB Infection (LTBI)

Goal: prevent progression to active disease.

• INH 300 mg daily for 9 months (preferred).
• Rifampin 600 mg daily for 4 months.
• Combination INH + Rifapentine weekly for 12 weeks (3HP regimen).

3. Multidrug‑Resistant TB (MDR‑TB)

Defined as resistance to at least INH and RIF.

• Longer (≈20 months) regimen using second‑line drugs: fluoroquinolones (levofloxacin or moxifloxacin), injectable agents (amikacin, kanamycin), bedaquiline, linezolid, and others.
• All‑oral regimens containing bedaquiline and pretomanid have shortened treatment to 6–9 months in many cases (NEJM, 2020).

4. Extensively Drug‑Resistant TB (XDR‑TB)

Resistance to INH, RIF, any fluoroquinolone, and at least one second‑line injectable.

• Requires individualized therapy based on DST, often including newer agents (bedaquiline, delamanid, pretomanid) and repurposed drugs (clofazimine, cycloserine).
• Treatment duration can exceed 24 months and carries higher toxicity.

5. Adjunctive Measures

• Corticosteroids – indicated for TB meningitis, pericardial TB, and severe pleural effusions.
• Surgery – Reserved for complications (e.g., massive hemoptysis, bronchiectasis, spinal instability).
• Supportive care – nutritional support, smoking cessation, management of comorbidities (HIV, diabetes).

Living with Koch Disease (Tuberculosis)

Successful treatment hinges on adherence and lifestyle modifications.

Medication Adherence

• Take medicines at the same time each day; use pillboxes or phone reminders.
• Attend all clinic visits for DOT or virtual check‑ins.
• Report side effects promptly; many can be managed without stopping therapy.

Nutrition & Hydration

• Consume a balanced diet rich in protein, vitamins (A, D, C) and minerals (iron, zinc).
• Aim for 1.5–2 g of protein/kg body weight daily if weight loss is significant.
• Stay hydrated to help thin sputum.

Infection Control at Home

• Ventilate rooms daily—open windows for at least 30 minutes.
• Sleep in a separate bedroom if possible until sputum is negative on three consecutive tests.
• Wear a surgical mask when coughing; cover mouth with a tissue.
• Regularly clean surfaces with disinfectant.

Physical Activity

Gentle exercise (walking, stretching) improves lung capacity and mood, but avoid strenuous activity if fatigue or breathlessness is severe.

Psychosocial Support

• Join a TB support group or reach out to community health workers.
• Address stigma—educate family and coworkers about the disease’s curability.

Follow‑up Monitoring

• Monthly sputum smear/culture until conversion (usually 2–3 months).
• Liver function tests if on INH, RIF, or PZA, especially in patients with pre‑existing liver disease.
• Visual acuity testing for ethambutol toxicity.

Prevention

• BCG vaccination – Provides variable protection against severe childhood TB (meningeal and miliary forms). Recommended in high‑burden countries.
• Screen high‑risk groups – HIV patients, close contacts of active cases, healthcare workers.
• Infection‑control measures – Adequate ventilation, UV germicidal lamps in health facilities, use of N95 respirators for staff.
• Prompt treatment of active cases – Reduces community transmission.
• Address social determinants – Improve housing, nutrition, and access to healthcare.

Complications

If untreated or inadequately treated, TB can cause serious, sometimes fatal, complications:

• Pulmonary cavitation – Leads to massive hemoptysis.
• Respiratory failure – Due to extensive parenchymal destruction.
• TB meningitis – Causes hydrocephalus, seizures, permanent neurological deficits.
• Spinal (Pott) disease – Vertebral collapse, spinal cord compression.
• Pericardial TB – Constrictive pericarditis.
• Disseminated (miliary) TB – Multiorgan involvement, high mortality.
• Drug‑resistant TB – Emerges from incomplete therapy, requiring toxic, prolonged regimens.

When to Seek Emergency Care

References

1. World Health Organization. Global Tuberculosis Report 2023.
2. Centers for Disease Control and Prevention. Tuberculosis (TB) Overview. Updated 2023.
3. Mayo Clinic. Tuberculosis Symptoms and Causes. Accessed April 2024.
4. Cleveland Clinic. Tuberculosis (TB) Treatment. 2023.
5. National Institute of Allergy and Infectious Diseases. Tuberculosis. Updated 2022.
6. World Health Organization. Treatment of drug‑susceptible and drug‑resistant TB. 2019.
7. New England Journal of Medicine. Bedaquiline‑containing regimens for MDR‑TB. 2020.

```